Gyre Therapeutics, Inc.Financials
|
|
Historical Financials
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 116,588,000 | 105,757,000 | 113,450,000 | 102,290,000 | 7,338,000 | 20,948,000 | - | 6,000 | 1,018,000 | 399,000 | |
| Cost of Revenue | 5,416,000 | 3,884,000 | 4,636,000 | 4,793,000 | - | - | - | - | - | - | |
| Gross Profit | 111,172,000 | 101,873,000 | 108,814,000 | 97,497,000 | - | - | - | - | - | - |
Sign up to view full financial statements
Create a free CapEdge account to access balance sheet, cash flow, and complete historical data.
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin (%) | |||||||||||
| R&D Expense | |||||||||||
| SG&A Expense | |||||||||||
| Total Operating Expenses | |||||||||||
| Operating Income or Loss | |||||||||||
| Operating Margin (%) | |||||||||||
| EBITDA | |||||||||||
| Non-Operating Income/Expense | |||||||||||
| Income Before Tax | |||||||||||
| Income Tax Expense | |||||||||||
| Income from Continuing Ops. | |||||||||||
| Net Income | |||||||||||
| Net Profit Margin (%) | |||||||||||
| Basic EPS | |||||||||||
| Diluted EPS | |||||||||||
| Basic Average Shares | |||||||||||
| Diluted Average Shares |
All numbers in thousands. Financial statements are in beta and sourced from EDGAR XBRL filings. Read the caveats.